Tuesday, October 1, 2019
6:30 AM
7:30 AM

Sunrise Fun Run

Want to get physical, physical?  Join us for a SynBioBeta SUNRISE FUN RUN, every morning of the conference at 6:30am. We’ll run down to the Ferry Building (~ 2 miles round trip) to see the beautiful sunrise over the San Francisco Bay!
InterContinental Mark Hopkins San Francisco
8:30 AM
10:00 AM

Registration

8:30 AM
9:45 AM

Exhibitor Hours

Exhibition Hall
10:00 AM
10:10 AM

Welcome

Main Stage
10:10 AM
10:40 AM

Keynote: A New Era in Genome Engineering

CRISPR is stuck in the sense that companies don’t yet have the ability to do multiplex gene editing at a cost structure that can realize its many hoped-for benefits. Inscripta aims to change that. It aims to break down barriers related to cost and intellectual property to enable wider use of gene editing on an unprecedented scale.
Main Stage
  • Kevin Ness (Inscripta)
  • Inscripta
    Inscripta
This session has a limited number of seats
Only 152 seats left
10:40 AM
11:10 AM

Synthetic Biology and the Future of Living Medicine

The idea of leveraging an organism’s intrinsic properties for medical benefits has existed for millennia. But in the last few years, synthetic biologists have revolutionized the idea of living medicines — engineered microorganisms that fight diseases, deliver therapeutic payloads, bolster the microbiome, and protect the skin.
Main Stage
  • Ena Cratsenburg (Ginkgo Bioworks)
  • Timothy Lu (Senti Biosciences)
  • Aoife Brennan (Synlogic)
11:10 AM
11:25 AM

Keynote: Ian Watson, White House Assistant Director of Biotechnology and Biosecurity

Ian Watson is the Assistant Director of Biotechnology & Biosecurity, Executive Office of the President, Office of Science, Technology & Policy. Mr. Watson will provide a perspective from the highest level of US government on the security applications and implications of biotechnology, and how the synthetic biology community can anticipate and address them.
Main Stage
This session has a limited number of seats
Only 211 seats left
11:25 AM
11:55 AM

America’s Biostrategy: Synthetic Biology as a National Priority

In recognition of the economic and national security importance of synthetic biology, countries like China and the UK have embarked on coordinated national strategies for research and development in academia and industry. This fireside chat will explore the efforts to create a national strategy in the United States, and what is needed for the US to maintain its strategic, economic, and scientific leadership in the global bioeconomy.
Main Stage
  • Erin Brodwin ( Business Insider)
  • Jason Kelly (Ginkgo Bioworks)
  • Lisa Porter (DoD)
This session has a limited number of seats
Only 157 seats left
11:55 AM
12:00 PM

Sponsored Lunch Announcement

Main Stage
  • Labcyte
    Labcyte
12:00 PM
4:00 PM

Exhibitor Hours

Exhibition Hall
12:00 PM
1:30 PM

Sponsored Lunch

Patio - 3rd Floor
  • Labcyte
    Labcyte
12:30 PM
1:15 PM

Partnering with the DoD

Learn about partnering with The Department of Defense, which has set biotechnology as a top ten technology priority. Most current biotech research focuses on agent detection, vaccines, and treatment. Future advances in biotechnology will improve the protection of both the general public and military personnel from biological agents, among numerous other potential applications.
Breakout Room 1
  • Alexander Titus (Office of the Under Secretary of Defense for Research & Engineering)
  • Lisa Porter (DoD)
This session has a limited number of seats
Only 46 seats left
12:30 PM
1:15 PM

Workshop: Labcyte - Miniaturization and Rapid Processing of TXTL Reactions Using Acoustic Liquid Handling

Past decades have seen significant advancements in synthetic biology. Recently, transcription-translation (TXTL) systems have gained popularity due to their ability to enable high-throughput screening applications. TXTL reactions transcribe input DNA into RNA, and RNA is then translated into protein in vitro. Because in vitro protein synthesis is decoupled from cellular functions, experimental cycle time can be greatly reduced. Here we assay DNA constructs using the Arbor Biosciences myTXTL technology with the Labcyte Echo 525 Liquid Handler. The Echo 525 Liquid Handler uses a transducer to acoustically dispense in 25 nL increments while maintaining a high flow rate of up to 5000 nL/s. Arbor Biosciences myTXTL® technology uses a transcription factor sigma 70 (σ70) to drive protein expression from p70 promoters. We assay p70 promoters in this study to drive fluorescent proteins in a variety of conditions in a miniaturized TXTL reaction.
Breakout Room 4
  • Jared Bailey (Labcyte)
  • Labcyte
    Labcyte
12:30 PM
1:15 PM

Workshop

Breakout Room 2
12:30 PM
1:15 PM

Rapid assembly of gene variant libraries and multi-gene pathways with semiconductor technologies

Engineering synthetic biological systems requires the design, build and testing of multi-gene networks. To optimize a synthetic system with the best combination of DNA parts, synthetic biologists need to test all possible variations of individual components and be able to screen in a combinatorial design space. But such combinatorial engineering approaches are hindered by the difficulty of simultaneously assembling numerous large, multi-gene constructs from a collection of DNA parts.  Here, we introduce our newly developed variant library synthesis platforms, which creates well-designed mutant libraries containing all desired variants with unbiased distribution. Additionally, our combinatorial library synthesis platform enables in-parallel construction of thousands of multiplexed gene variants in an efficient and economical way. Both platforms utilize our patented semiconductor-based oligonucleotide microarray fabrication technology allowing complete control over codon usage and amino acid distribution. Libraries generated using this method are highly customizable and capable of generating over 1x108 variants. As a result, our platform enables faster, easier, and more cost-effective engineering of metabolic pathways and microbial strains in comparison to alternative approaches. 
Breakout Room 3
Workshop
This session has a limited number of seats
Only 195 seats left
12:30 PM
1:15 PM

Workshop

Breakout Room 5
1:30 PM
2:15 PM

Lightning Talks

Main Stage
  • Troy Lionberger (Berkeley Lights)
  • Josh Silverman (Aromyx)
  • Mike Cox (Anaerobe Systems)
  • Laura Whitman (Agilent Technologies)
  • Matt Angle (Paradromics)
  • Maia Smith (AbCellera)
  • Kristin Ellis (Opentrons)
  • Sajith Wickramasekara (Benchling)
  • Reed Molbak (Benchling)
  • Linda Molnar (America’s Seed Fund)
1:30 PM
2:15 PM

The new biopharma: immuno-engineering's mission to drug impossible targets

Computational immuno-engineers. Our mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). In monoclonal therapeutics, our integration of computational immunology, bioengineering and robotics has enabled us to create a pipeline of molecules with unprecedented biophysical properties, while also supporting all of our partners with thousands of high affinity developable antibodies against any drug target of interest. In vaccine science, our Centivax technology is producing broad-spectrum vaccines against rapidly mutating pathogens like influenza and HIV.
Breakout Room 1
  • Jacob Glanville (Distributed Bio)
  • Rachel Hovde (Chimera)
  • Distributed Bio
    Distributed Bio
This session has a limited number of seats
Only 71 seats left
1:30 PM
2:15 PM

Cannabinoids

The two most well studied/abundant compounds derived from the cannabis plant (THC and CBD) are FDA approved products and are at the core of a multi-billion dollar wellness market. These two compounds represent only a small fraction of all the 100s of cannabinoids, flavonoids, and sterols produced by the cannabis plant that may have medicinal value. This diversity in natural products represents an untapped reservoir of potential therapeutic agents that can target a wide range of indications. Synthetic biology has been at the core of accessing hard to source natural products through genetic manipulation of microorganisms and has a role to play in unlocking the therapeutic potential of the cannabis plant. What other compounds are inside the cannabis plant? What is next for the industry and how can synthetic biology enable new growth? In this talk Dr. Jason Poulos, CEO of Librede, will discuss these topics and present a range of opportunities that await the synbiobeta community.
Breakout Room 2
  • Michael Freeman (Raymond James Ltd.)
  • Michael Mendez (Renew Biopharma)
  • Elizabeth Conway (Surterra Wellness)
  • Jason Poulos (Librede)
This session has a limited number of seats
Only 32 seats left
1:30 PM
2:15 PM

Synthetic Biology & The Green New Deal

New York representative Alexandria Ocasio-Cortez championed a version that would see the US transition to 100 percent renewable energy in only 10 years even as members of the synthetic biology community took part in active discussions around how synthetic biology could help the Green New Deal — and vice versa. While details are still being fleshed out, one thing is certain: the Green New Deal stands to affect the change the public wants to see, with an emphasis on economic, social, and environmental justice. 
Breakout Room 4
  • Rob Carlson (Bioeconomy Capital)
  • Will Canine (Opentrons)
  • Keira Havens
  • Zack Exley (New Consensus)
1:30 PM
2:15 PM

Breakout Session: Open Session

Breakout Room 5
This session has a limited number of seats
Only 86 seats left
1:30 PM
2:15 PM

Breakout Session: Biopharma

Breakout Room 3
  • Sandor Schoichet (Meridian Management Consultants)
  • Rob Mcbride (Felix Biotechnology)
  • Jacob Becraft (Strand Therapeutics)
  • Christian Groendahl (SNIPR BIOME)
  • Kunwoo Lee (GenEdit)
This session has a limited number of seats
Only 18 seats left
2:15 PM
2:30 PM

Break

2:30 PM
3:15 PM

DNA Data Storage

As we enter the century of biotechnology, our ability to read, write, and edit DNA is disrupting everything from human health to manufacturing. The next disruption to take place could be in the world of data storage. Learn about where we’ve been, where we are now, and where we are going — and what it will take to get there.
Main Stage
  • Megan Molteni (WIRED)
  • Bill Peck (Twist Bioscience)
  • Karin Strauss (Microsoft)
  • Bill efcavitch (Molecular Assemblies Inc)
  • Molecular Assemblies
    Molecular Assemblies
This session has a limited number of seats
Only 214 seats left
2:30 PM
3:15 PM

What's Your Bio Strategy - The Future of Biomanufacturing

Learn about biomanufacturing of chemicals and materials and the challenges facing the field that synthetic biology is poised to address.
Breakout Room 1
  • Mark Bünger (Innovation Lab)
  • Riccardo LoCascio (Novozymes)
2:30 PM
3:15 PM

Cyanobacterial and Algal Synthetic Biology

Cyanobacteria and algae are emerging as attractive hosts for synthetic biology applications, ranging from metabolic engineering for the production of industrial biochemicals to microbial energy storage. Learn about the applications, opportunities, commercial success stor ies, and what the future holds for these organisms.  
Breakout Room 2
  • Claudia Vickers (CSIRO)
  • Ajit Sapre (Reliance Industries Limited)
  • Charles Dimmler (Checkerspot, Inc.)
  • Elliot Roth (Spira)
  • James Brown (Bondi Bioworks)
This session has a limited number of seats
Only 38 seats left
2:30 PM
3:15 PM

Biosecurity

Synthetic biology is a catalyst that will transform manufacturing and our economy into a bio-centric engine. This shift will require new ways of measuring, securing, and nurturing advanced biotechnology as it enters most every aspect of our lives. Learn how we can think and act on aspects of policy, biosecurity, and the bioeconomy — both individually and collectively — so that our bioeconomy and our society may flourish for years to come.
Breakout Room 3
  • Sarah Carter (Science Policy Consulting)
  • Milana Trounce (Stanford Medical School)
  • Gabriel Lopez (Synvivia)
This session has a limited number of seats
Only 167 seats left
2:30 PM
3:15 PM

What does it take to create a strong partnership between companies?

This panel will explore collaborations between companies from the introduction stage to design and formation of a productive working relationship onto the ins and outs of fostering a partnership that creates a winning situation on both sides. Panel will be mediated by Erica Pascal (Ingensity IP).
Breakout Room 4
  • Erica Pascal (Ingensity IP)
  • Jun Axup (IndieBio)
  • Miller Tran (Triton Algae Innovations)
  • Laura Smoliar (Berkeley Catalyst Fund)
  • Ranjan Patnaik (Clara Foods)
  • InGensity IP
    InGensity IP
2:30 PM
3:15 PM

Synthetic Biology and the Workforce of the Future

Fluency in the skills and concepts of synthetic biology ensures that the next generation will thrive in the growing bioeconomy. Corporate leaders must also be courageous in designing workplaces that not only meet stakeholder needs, but also cultivate diverse innovators. In this session, speakers will discuss how synthetic biology will impact the workplace of the future.
Breakout Room 5
3:15 PM
4:00 PM

Sponsored Coffee Break

Exhibition Hall